Payment overview · 2025
General Payments
$413.11
21 reported records · 14 companies
Healthcare provider profile · identity verified
Della Ellis Evans, M. D.
Allopathic & Osteopathic Physicians|Family Medicine|Geriatric Medicine · EVANSVILLE, IN · NPI 1588644744
Verified facts
What the public records show
CMS Open Payments records show Della Ellis Evans, M. D. received $413.11 in general payments during 2025 across 21 reported records.
Sumitomo Pharma America, Inc. accounted for 19.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 17 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Arexvy, Eliquis, Gemtesa, Ozempic, Shingrix, Trelegy Ellipta.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 93 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Symbicort by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AREXVY as an associated drug or biological on 47563 records involving 28786 distinct recipient NPIs. Public Medicare Part D data also shows 35 claims for Arexvy by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SHINGRIX as an associated drug or biological on 43515 records involving 26794 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Shingrix by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 35 claims for Trelegy Ellipta by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 33 claims for Entresto by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported KISQALI as an associated drug or biological on 31637 records involving 7959 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Kisqali by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 480 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Paxlovid by this doctor in 2024.
Sumitomo Pharma America, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported GEMTESA as an associated drug or biological on 61692 records involving 22152 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Gemtesa by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $81.43 | 19.7% | 4 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $52.30 | 12.7% | 3 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $39.25 | 9.5% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $29.20 | 7.1% | 2 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $28.08 | 6.8% | 1 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $24.12 | 5.8% | 1 | 2025 |
| Insulet Corporation | Unresolved — no canonical attribution shown | $23.85 | 5.8% | 1 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $23.09 | 5.6% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $22.58 | 5.5% | 1 | 2025 |
| Viatris Specialty LLC | Unresolved — no canonical attribution shown | $20.61 | 5.0% | 1 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $20.07 | 4.9% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $17.36 | 4.2% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $16.88 | 4.1% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $14.29 | 3.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $413.11 | 21 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $63.37 | 3 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $43.15 | 2 | 2025 |
Source payment records
|
|||||
| MYFEMBREE Normalized: myfembree |
Drug | Sumitomo Pharma America, Inc. | $38.28 | 2 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $33.58 | 2 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $33.58 | 2 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $29.20 | 2 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $28.08 | 1 | 2025 |
Source payment records
|
|||||
| Omnipod Normalized: omnipod |
Device | Insulet Corporation | $23.85 | 1 | 2025 |
Source payment records
|
|||||
| WATCHMAN FLX Normalized: watchman flx |
Device | Boston Scientific Corporation | $23.09 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $22.58 | 1 | 2025 |
Source payment records
|
|||||
| YUPELRI Normalized: yupelri |
Drug | Viatris Specialty LLC | $20.61 | 1 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $20.07 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $18.72 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $17.36 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $17.36 | 1 | 2025 |
Source payment records
|
|||||
| ZERBAXA Normalized: zerbaxa |
Drug | Merck Sharp & Dohme LLC | $16.88 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $14.29 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| AREXVY arexvy |
2025 | Arexvy | 2024 | 35 | exact normalized | Medicare Part D |
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 480 | exact normalized | Medicare Part D |
| GEMTESA gemtesa |
2025 | Gemtesa | 2024 | 23 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 20 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| SHINGRIX shingrix |
2025 | Shingrix | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 35 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
93 | 17 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | AREXVY open payments reported associated product |
CMS Open Payments — General Payments 47563 supporting records · 28786 recipient NPIs · example record 1190332445 |
Arexvy · 2024 Exact normalized brand match · 1 Part D row |
35 | 30 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | SHINGRIX open payments reported associated product |
CMS Open Payments — General Payments 43515 supporting records · 26794 recipient NPIs · example record 1190332452 |
Shingrix · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
35 | suppressed by CMS |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
33 | suppressed by CMS |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | KISQALI open payments reported associated product |
CMS Open Payments — General Payments 31637 supporting records · 7959 recipient NPIs · example record 1200004789 |
Kisqali · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
480 | 66 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
21 | 21 |
| Sumitomo Pharma America, Inc. Exact reporting entity; no affiliate inference |
2025 | GEMTESA open payments reported associated product |
CMS Open Payments — General Payments 61692 supporting records · 22152 recipient NPIs · example record 1176593503 |
Gemtesa · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1164 | 187 |
| Levothyroxine Sodium | Levothyroxine Sodium | 1057 | 173 |
| Amlodipine Besylate | Amlodipine Besylate | 786 | 177 |
| Sertraline Hcl | Sertraline Hcl | 662 | 83 |
| Lisinopril | Lisinopril | 528 | 110 |
| Furosemide | Furosemide | 515 | 110 |
| Losartan Potassium | Losartan Potassium | 506 | 99 |
| Eliquis | Apixaban | 480 | 66 |
| Gabapentin | Gabapentin | 473 | 83 |
| Omeprazole | Omeprazole | 463 | 109 |
| Memantine Hcl | Memantine Hcl | 402 | 54 |
| Pantoprazole Sodium | Pantoprazole Sodium | 385 | 67 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 374 | 88 |
| Metoprolol Succinate | Metoprolol Succinate | 372 | 83 |
| Potassium Chloride | Potassium Chloride | 353 | 66 |
| Carvedilol | Carvedilol | 329 | 46 |
| Metoprolol Tartrate | Metoprolol Tartrate | 319 | 50 |
| Escitalopram Oxalate | Escitalopram Oxalate | 291 | 44 |
| Tamsulosin Hcl | Tamsulosin Hcl | 283 | 41 |
| Donepezil Hcl | Donepezil Hcl | 253 | 42 |
| Clopidogrel | Clopidogrel Bisulfate | 251 | 44 |
| Hydrochlorothiazide | Hydrochlorothiazide | 247 | 59 |
| Trazodone Hcl | Trazodone Hcl | 224 | 49 |
| Lorazepam | Lorazepam | 218 | 49 |
| Metformin Hcl | Metformin Hcl | 216 | 55 |
| Famotidine | Famotidine | 211 | 46 |
| Simvastatin | Simvastatin | 206 | 56 |
| Buspirone Hcl | Buspirone Hcl | 187 | 31 |
| Mirtazapine | Mirtazapine | 180 | 44 |
| Montelukast Sodium | Montelukast Sodium | 168 | 29 |
| Pravastatin Sodium | Pravastatin Sodium | 167 | 50 |
| Tramadol Hcl | Tramadol Hcl | 162 | 46 |
| Hydralazine Hcl | Hydralazine Hcl | 158 | 33 |
| Allopurinol | Allopurinol | 144 | 35 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 135 | 44 |
| Citalopram Hbr | Citalopram Hydrobromide | 135 | 29 |
| Levetiracetam | Levetiracetam | 129 | 13 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 124 | 26 |
| Alprazolam | Alprazolam | 123 | 37 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 122 | 22 |
| Prednisone | Prednisone | 117 | 55 |
| Divalproex Sodium | Divalproex Sodium | 112 | 11 |
| Bupropion Xl | Bupropion Hcl | 111 | 18 |
| Warfarin Sodium | Warfarin Sodium | 109 | 20 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 105 | 31 |
| Amiodarone Hcl | Amiodarone Hcl | 104 | 14 |
| Quetiapine Fumarate | Quetiapine Fumarate | 96 | 11 |
| Farxiga | Dapagliflozin Propanediol | 93 | 17 |
| Clonazepam | Clonazepam | 87 | 18 |
| Ondansetron Hcl | Ondansetron Hcl | 84 | 38 |
| Duloxetine Hcl | Duloxetine Hcl | 82 | 26 |
| Xarelto | Rivaroxaban | 80 | suppressed |
| Cephalexin | Cephalexin | 79 | 57 |
| Zolpidem Tartrate | Zolpidem Tartrate | 77 | 15 |
| Atenolol | Atenolol | 76 | 18 |
| Pregabalin | Pregabalin | 76 | 13 |
| Fluticasone Propionate | Fluticasone Propionate | 75 | 32 |
| Meloxicam | Meloxicam | 75 | 24 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 75 | 11 |
| Ezetimibe | Ezetimibe | 74 | 19 |
| Latanoprost | Latanoprost | 73 | 17 |
| Myrbetriq | Mirabegron | 71 | suppressed |
| Galantamine Hbr | Galantamine Hbr | 65 | suppressed |
| Loperamide | Loperamide Hcl | 65 | 31 |
| Alendronate Sodium | Alendronate Sodium | 64 | 18 |
| Jardiance | Empagliflozin | 64 | 13 |
| Primidone | Primidone | 64 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 62 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 62 | 22 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 61 | 17 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 60 | 18 |
| Nystatin | Nystatin | 60 | 26 |
| Synthroid | Levothyroxine Sodium | 60 | 15 |
| Ziprasidone Hcl | Ziprasidone Hcl | 60 | suppressed |
| Januvia | Sitagliptin Phosphate | 59 | 11 |
| Tizanidine Hcl | Tizanidine Hcl | 59 | 27 |
| Midodrine Hcl | Midodrine Hcl | 57 | 12 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 56 | 11 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 56 | suppressed |
| Olanzapine | Olanzapine | 54 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 52 | 12 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 51 | 13 |
| Spironolactone | Spironolactone | 51 | 14 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 49 | 23 |
| Fluoxetine Hcl | Fluoxetine Hcl | 48 | 14 |
| Aripiprazole | Aripiprazole | 47 | suppressed |
| Sucralfate | Sucralfate | 46 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 45 | 32 |
| Dicyclomine Hcl | Dicyclomine Hcl | 45 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 45 | 14 |
| Albuterol Sulfate | Albuterol Sulfate | 43 | 11 |
| Nyamyc | Nystatin | 42 | 12 |
| Diltiazem 24hr Er (La) | Diltiazem Hcl | 41 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 41 | suppressed |
| Fluconazole | Fluconazole | 40 | 17 |
| Tradjenta | Linagliptin | 40 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 39 | suppressed |
| Azithromycin | Azithromycin | 38 | 33 |
| Finasteride | Finasteride | 38 | suppressed |
| Hydrocortisone | Hydrocortisone | 38 | 11 |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 38 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 38 | suppressed |
| Linzess | Linaclotide | 37 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 37 | 11 |
| Doxazosin Mesylate | Doxazosin Mesylate | 36 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 36 | suppressed |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 35 | 30 |
| Oxycodone Hcl | Oxycodone Hcl | 35 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 35 | suppressed |
| Baclofen | Baclofen | 34 | 11 |
| Ondansetron Odt | Ondansetron | 34 | 16 |
| Torsemide | Torsemide | 34 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 34 | 20 |
| Acyclovir | Acyclovir | 33 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 33 | suppressed |
| Cilostazol | Cilostazol | 33 | suppressed |
| Entresto | Sacubitril/Valsartan | 33 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 33 | suppressed |
| Lovastatin | Lovastatin | 33 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 33 | 14 |
| Glimepiride | Glimepiride | 32 | 11 |
| Insulin Lispro | Insulin Lispro | 32 | suppressed |
| Irbesartan | Irbesartan | 32 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 30 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 30 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 30 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 28 | suppressed |
| Timolol Maleate | Timolol Maleate | 28 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 27 | 15 |
| Incruse Ellipta | Umeclidinium Bromide | 27 | suppressed |
| Ketoconazole | Ketoconazole | 27 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 27 | 12 |
| Venlafaxine Hcl | Venlafaxine Hcl | 27 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 27 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 26 | 21 |
| Nitroglycerin | Nitroglycerin | 26 | 17 |
| Silver Sulfadiazine | Silver Sulfadiazine | 26 | suppressed |
| Vascepa | Icosapent Ethyl | 26 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 25 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 25 | suppressed |
| Ramipril | Ramipril | 25 | suppressed |
| Topiramate | Topiramate | 25 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 24 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 24 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 24 | suppressed |
| Namzaric | Memantine Hcl/Donepezil Hcl | 24 | suppressed |
| Novolog Flexpen | Insulin Aspart | 24 | suppressed |
| Silodosin | Silodosin | 24 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 24 | suppressed |
| Gemtesa | Vibegron | 23 | suppressed |
| Glipizide | Glipizide | 23 | suppressed |
| Glipizide Er | Glipizide | 22 | suppressed |
| Anastrozole | Anastrozole | 21 | suppressed |
| Lansoprazole | Lansoprazole | 21 | suppressed |
| Lumigan | Bimatoprost | 21 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 21 | 14 |
| Paxlovid | Nirmatrelvir/Ritonavir | 21 | 21 |
| Amitriptyline Hcl | Amitriptyline Hcl | 20 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 20 | 12 |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 20 | 11 |
| Metoclopramide Hcl | Metoclopramide Hcl | 20 | suppressed |
| Ozempic | Semaglutide | 20 | suppressed |
| Movantik | Naloxegol Oxalate | 19 | suppressed |
| Amoxicillin | Amoxicillin | 18 | 15 |
| Bumetanide | Bumetanide | 18 | suppressed |
| Calcitriol | Calcitriol | 18 | suppressed |
| Diazepam | Diazepam | 18 | suppressed |
| Insulin Glargine-Yfgn | Insulin Glargine-Yfgn | 18 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 18 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 18 | suppressed |
| Cefdinir | Cefdinir | 17 | 16 |
| Celecoxib | Celecoxib | 17 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 17 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 17 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 17 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 17 | suppressed |
| Lamotrigine | Lamotrigine | 16 | suppressed |
| Letrozole | Letrozole | 16 | suppressed |
| Lubiprostone | Lubiprostone | 16 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 16 | suppressed |
| Renvela | Sevelamer Carbonate | 16 | suppressed |
| Rivastigmine | Rivastigmine | 16 | suppressed |
| Rivastigmine | Rivastigmine Tartrate | 16 | suppressed |
| Sotalol | Sotalol Hcl | 16 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 16 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 15 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 15 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 15 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 14 | suppressed |
| Atropine Sulfate | Atropine Sulfate | 14 | suppressed |
| Brimonidine Tartrate-Timolol | Brimonidine Tartrate/Timolol | 14 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 14 | suppressed |
| Estradiol | Estradiol | 14 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 14 | suppressed |
| Nystop | Nystatin | 14 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 14 | suppressed |
| Verapamil Er | Verapamil Hcl | 14 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 14 | suppressed |
| Dapagliflozin | Dapagliflozin Propanediol | 13 | suppressed |
| Lagevrio (Eua) | Molnupiravir | 13 | 11 |
| Leflunomide | Leflunomide | 13 | suppressed |
| Methotrexate | Methotrexate Sodium | 13 | suppressed |
| Risperidone | Risperidone | 13 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 13 | suppressed |
| Armour Thyroid | Thyroid,pork | 12 | suppressed |
| Arnuity Ellipta | Fluticasone Furoate | 12 | suppressed |
| Chlorthalidone | Chlorthalidone | 12 | suppressed |
| Exemestane | Exemestane | 12 | suppressed |
| Kisqali | Ribociclib Succinate | 12 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 12 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 12 | suppressed |
| Abiraterone Acetate | Abiraterone Acetate | 11 | suppressed |
| Brimonidine Tartrate | Brimonidine Tartrate | 11 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 11 | suppressed |
| Ibuprofen | Ibuprofen | 11 | suppressed |
| Klor-Con 10 | Potassium Chloride | 11 | suppressed |
| Methimazole | Methimazole | 11 | suppressed |
| Nadolol | Nadolol | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $413.11 · 21 records | Sumitomo Pharma America, Inc. | AREXVY, Auvelity, BREZTRI, Cologuard Collection Kit, ELIQUIS, GEMTESA, LEQVIO, MYFEMBREE, NURTEC ODT, Omnipod, Ozempic, REXULTI, SHINGRIX, TRELEGY ELLIPTA, WATCHMAN FLX, YUPELRI, ZERBAXA | 11 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Arexvy play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error